There is growing evidence indicating that CXCL7 is expressed by a variety of tumors, including renal cell carcinoma, breast cancer, and colorectal cancer, and that its aberrant expression can serve as a valid marker for multiple systemic malignancies, thus helping clinicians in early identification of malignancies and monitoring of treatment efficacy (Wang et al., 2013; Dufies et al., 2017; Li et al., 2021). This evidence concerns the gene PPBP and renal cell carcinoma.